- Home
- ODD vs PRCT Comparison
ODD vs PRCT Comparison
Compare ODD & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODD
- PRCT
- Stock Information
- Founded
- ODD 2018
- PRCT 2009
- Country
- ODD Israel
- PRCT United States
- Employees
- ODD N/A
- PRCT N/A
- Industry
- ODD
- PRCT Medical Specialities
- Sector
- ODD
- PRCT Health Care
- Exchange
- ODD Nasdaq
- PRCT Nasdaq
- Market Cap
- ODD 3.8B
- PRCT 3.2B
- IPO Year
- ODD 2023
- PRCT 2021
- Fundamental
- Price
- ODD $71.72
- PRCT $60.22
- Analyst Decision
- ODD Buy
- PRCT Strong Buy
- Analyst Count
- ODD 8
- PRCT 7
- Target Price
- ODD $59.00
- PRCT $90.00
- AVG Volume (30 Days)
- ODD 1.2M
- PRCT 819.9K
- Earning Date
- ODD 08-06-2025
- PRCT 07-31-2025
- Dividend Yield
- ODD N/A
- PRCT N/A
- EPS Growth
- ODD 45.36
- PRCT N/A
- EPS
- ODD 1.74
- PRCT N/A
- Revenue
- ODD $703,488,000.00
- PRCT $249,121,000.00
- Revenue This Year
- ODD $24.46
- PRCT $47.40
- Revenue Next Year
- ODD $20.26
- PRCT $31.55
- P/E Ratio
- ODD $41.30
- PRCT N/A
- Revenue Growth
- ODD 26.83
- PRCT 59.36
- 52 Week Low
- ODD $32.71
- PRCT $47.04
- 52 Week High
- ODD $79.18
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- ODD 55.62
- PRCT 52.43
- Support Level
- ODD $69.63
- PRCT $58.34
- Resistance Level
- ODD $74.50
- PRCT $61.43
- Average True Range (ATR)
- ODD 2.65
- PRCT 2.61
- MACD
- ODD -1.15
- PRCT -0.37
- Stochastic Oscillator
- ODD 25.84
- PRCT 38.21
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.